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Abstract
Background: To compare the outcomes of gastric, colon, lung, and breast cancer patients with and without
rheumatic diseases (RD).
Methods: This retrospective study compared the cancer survival rates of a cohort of 122 cancer patients with
rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), dermatomyositis/polymyositis (DM/PM), or systemic
sclerosis with that of a cohort of 366 age-, sex-, and, cancer type-matched patients without RD who received
medical care from 2000 to 2014. Staging, comorbidities, and functional status were ascertained. Survival was
compared using the Kaplan-Meier method. Relative risk of death was estimated as a hazard ratio (HR) using Cox
regression analysis.
Results: The mean age of the RD patients at the time of cancer diagnosis was 58.7 ± 11.5 years. The overall survival
rate of gastric cancer patients did not differ between the cohorts. The survival of lung or breast cancer was worse
in patients with RA or DM/PM than in those without RD (all, p < 0.05). After adjusting for cancer stage, comorbidity
index, performance status and age at the time of cancer diagnosis (as well as interstitial lung disease for lung
cancer group), the mortality rate among lung cancer patients with RA was significantly higher (HR, 1.81; 95 % CI, 1.
03–3.18) than that of lung cancer patients without RD, whereas SSc was associated with decreased mortality of
lung cancer (HR, 0.16; 95 % CI, 0.04–0.58). DM/PM were associated with increased mortality of breast cancer patients
(HR, 297.39; 95 % CI, 4.24–20842.33).
Conclusions: RA and DM/PM seemed to be associated with a higher mortality in patients with lung or breast
cancers, whereas SSc seemed to be associated with decreased mortality in patients with lung cancer. It is warranted
to explore the survival effect of tailored cancer treatments according to specific RD.
Keywords: Rheumatic diseases, Cancer, Staging, Mortality, Survival
Background
Rheumatic disease (RD) is characterized by chronic sys-
temic inflammation involving multiple organs. Unopposed
inflammation and the production of cytokines, growth
hormones, and toxic reactive oxygen species may promote
the progression of precancerous cells into a clinically
significant cancer [1]. Impaired immune surveillance
associated with underlying RD and long-term immuno-
suppressive therapy might not only promote the survival
and proliferation of cancer cells, but also increase the risk
of infection, a main cause of death during cancer treat-
ment [2–4]. In short, cancer patients with RD may have a
worse prognosis than those without RD. Conversely,
cytotoxic autoimmune cells in patients with RD might
eliminate cancer cells better. Also, the prolonged use of
non-steroidal anti-inflammatory drugs (NSAIDs) and anti-
metabolites such as methotrexate might inhibit proliferative
stimuli, thereby inhibiting cancer development and pro-
gression [5, 6]. Furthermore, the close medical monitoring
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received by RD patients during longitudinal follow up
might lead to early detection of cancers and more prompt
treatment, ultimately resulting in a better outcome [7, 8].
Although a solid body of evidence supports a close
association between RD and incident cancers, data re-
garding outcomes for RD patients who develop incident
cancer are scarce and often conflicting [9, 10]. We previ-
ously reported that the cancer outcome in patients with
Takayasu arteritis was excellent, suggesting that the
underlying autoimmune disease might not negatively in-
fluence cancer outcome, at least for certain RDs [11].
Here, we aimed to investigate whether cancer patients
with specific RDs have a worse outcome than those with-
out RDs by comparing the survival of RD patients with
four common cancers (i.e., gastric, colon, lung, and breast)
with that of matched cancer patients without RDs.
Methods
Patients
The medical records of patients with rheumatoid arthritis
(RA), systemic lupus erythematosus (SLE), systemic scler-
osis (SSc), and dermatomyositis/polymyositis (DM/PM)
that received longitudinal clinical care at Seoul National
University Hospital from January 2000 to April 2014 were
retrospectively reviewed, and those that had developed a
gastric, colon, lung, or breast cancer after their RD diag-
nosis were enrolled in the study (these patients comprised
the RD-exposed cancer cohort). The patients in whom
cancer was diagnosed before RD were excluded, since the
aim of the study was to investigate the effects of RD on
the cancer outcome. RA, SLE, SSc and PM/DM were
diagnosed according to the 1987 revised classification
criteria of the American College of Rheumatology (ACR)
for RA, the 1997 ACR classification criteria for SLE, the
1980 preliminary ACR classification criteria for SSc, and
the Bohan and Peter criteria for PM or DM, respectively
[12–15]. The non-RD-exposed cancer cohort comprised
366 age-, sex-, and cancer site-matched patients without
RD who were diagnosed with cancer in the same year as
the RD patients and who received medical care at the
same hospital. These patients were randomly selected
from the medical record archive so as to achieve a match-
ing ratio of 1 to 3 for each RD. The study was approved
by the Institutional Review Board of the Seoul National
University Hospital. The need for patient consent was
waived by the Review Board as the study involved minimal
risk and its retrospective nature meant that no identifiable
information was used.
Cancer assessment
A complete data set for each cancer, including histology,
stage, and treatment, was obtained. All cancer cases
were diagnosed histopathologically and confirmed by
biopsy. Cancers were staged according to the American
Joint Committee on Cancer (AJCC) 7th staging system.
The Eastern Cooperative Oncology Group performance
status (ECOG-PS) and the Charlson comorbidity index
at the time of cancer diagnosis were estimated after
reviewing electronic medical records. An ECOG-PS of 0
indicates that the patient is asymptomatic and a score of
1 indicates that patient is restricted in terms of strenu-
ous activity but is able to ambulate and carry out light
work; however, an ECOG-PS ≥2 indicates a significant
limitation in performance status [16]. The Charlson co-
morbidity index predicts 10-year mortality for a patient
who may have a range of 22 comorbid conditions, in-
cluding cardiovascular disease and lung disease [17].
The index sums the assigned scores for each comorbid
condition, e.g., connective tissue disease is assigned a
score of 1, while a malignant tumor is assigned a score
of 6. In this study, the scores for connective tissue dis-
ease and cancer were omitted from the Charlson comor-
bidity index.
Statistical analysis
Student t-tests or analysis of variance (ANOVA) were
used to compare continuous variables between groups
and the Chi-square or Fisher’s exact test were used to
compare categorical variables. Survival curves were gen-
erated using the Kaplan-Meier method. Differences in
survival were compared using the log-ranks test. Follow
up began at the time of cancer diagnosis and was cen-
sored at the time of death or on the last day on which
survival status was followed up, whichever came first.
The survival status of the all patients was ascertained
using the National Death Register of Statistics Korea
(www.kostat.go.kr). The relative risk of death was esti-
mated using Cox’s proportional hazard ratio (HR) for
survival by adjusting for stage, ECOG performance sta-
tus, Charlson comorbidity index, and age in years at the
time of cancer diagnosis. HR for lung cancer mortality
was adjusted for the interstitial lung disease (ILD) status
as well. P ≤0.05 was considered significant. All analyses
were performed using IBM SPSS (statistics version 19.0,
Chicago, IL, USA).
Results
Demographic characteristics of RD patients with cancer
During the follow-up period, 122 RD patients with one
of the four selected types of incident cancer were identi-
fied. RA was the most common RD (80 patients;
65.6 %), followed by DM/PM (16 patients; 13.1 %), SSc
(13 patients; 10.7 %), and SLE (13 patients; 10.7 %). The
mean age at RD diagnosis was 52.4 ± 13.5 years (Table 1).
Except for the DM/PM group, the number of females
was higher than that of males. There were 28 cases of
gastric cancer (23.0 %), 23 cases of colon cancer
(18.9 %), 44 cases of lung cancer (36.1 %), and 27 cases
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of breast cancer (22.1 %). The mean age of the RD pa-
tients at the time of cancer diagnosis was 58.7 ±
11.5 years. The mean time from RD diagnosis to cancer
diagnosis was 5.8 [range: 0, 36.3] years. Notably, the
mean time between DM/PM and cancer diagnoses was
2.2 [range: 0, 8.4] years. The time between the breast
cancer and DM/PM diagnosis was relatively longer as
compared to gastric, colon and lung cancer (Additional
file 1: Table S1).
Characteristics of RD patients with cancer
The ECOG performance score for RD patients with
colon cancer was better than that for their matched
non-RD counterparts whereas that for RD patients with
lung cancer was worse (Table 2, upper row).
Although the proportion of RD patients with gastric,
colon, and lung cancer with a Charlson comorbidity score
≥1 was greater than that of matched cancer patients with-
out RD, the difference was significant for RD patients with
colon cancer (65.2 % for patients with RD vs. 33.3 % for
patients without RD; p = 0.025) and those with lung can-
cer (50.0 % for patients with RD vs. 32.3 % for patients
without RD; p = 0.047) (Table 2, middle row).
Significantly more stage 1 breast cancers were detected
in RD patients than in their matched counterparts with-
out RD (51.9 % vs. 29.6 %, respectively; p = 0.036). Stage
IV lung cancer was more prevalent and stage II less
prevalent in RD patients than in their matched counter-
parts without RD (36.4 % vs. 10.5 %; p < 0.001 for stage
IV and 11.4 % vs. 57.9 %; p < 0.001 for stage II) (Table 2,
bottom rows). Staging of gastric and colon cancers did
not differ between the two groups.
Cancer mortality in RD patients versus non-RD patients
During the follow-up period, 45 (36.9 %) of the 122 pa-
tients with RD died. One SSc patient with colon cancer
died due to progression of SSc-associated interstitial
lung disease (ILD). One RA patient with breast cancer
died of congestive heart failure (n = 1) and another of
old age (n = 1). The remaining 42 (93.3 %) of 45 deaths
occurred due to the cancer progression or complications
during cancer treatment (Table 3).
The overall survival of patients with gastric cancer did
not differ between the two groups (Fig. 1a). Of those
with colon cancer, one patient with SSc had a worse out-
come than their matched counterparts without RD
(Fig. 1b). Mortality was significantly worse for lung and
breast cancer patients with RA or DM/PM than for
those without RD (Fig. 1c and d).
Next, the relative risk of RD with respect to mortality
was estimated after adjusting for cancer stage, comorbid-
ity index, performance status, and age at the time of
cancer diagnosis. In case of lung cancer, the presence of
ILD was also considered for HR calculation. Compared
with matched cancer patients without RD, RA was asso-
ciated with a significant increase in the mortality of lung
cancer (HR, 1.81; 95 % CI, 1.03–3.18 (Fig. 2). DM/PM
was associated with a 297.39-fold increase in mortality
Table 1 Characteristics of 122 patients with rheumatic diseases and 366 cancer-matched controls without RD
RA (n = 80) SLE (n = 13) SSc (n = 13) DM/PM (n = 16) All RD (n = 122) Non-RD (n = 366)
Female, n (%) 59 (73.8) 13 (100.0) 10 (76.9) 6 (37.5) 88 (72.1) 264 (72.1)
Age at RD dx, yrs, 54.7 ± 12.8 42.4 ± 12.9 45.6 ± 16.1 58.2 ± 9.9 52.4 ± 13.5 N/A
Age at cancer dx, yrs, 60.2 ± 11.3 52.2 ± 9.7 54.2 ± 13.9 59.7 ± 9.3 58.7 ± 11.5 58.6 ± 11.6
Follow-up duration, yrs 14.4 ± 12.0 17.3 ± 10.2 10.7 ± 7.1 13.0 ± 11.2 12.8 ± 9.7 12.8 ± 9.7
Cancer type, n (%)
Stomach 18 (22.2) 4 (30.8) 2 (15.4) 4 (25.0) 28 (23.0) 83 (22.7)
Colon 16 (20.0) 3 (23.1) 1 (7.7) 3 (18.8) 23 (18.9) 69 (18.9)
Lung 28 (35.0) 0 (0) 10 (76.9) 6 (37.5) 44 (36.1) 133 (36.3)
Breast 18 (22.5) 6 (46.2) 0 (0.0) 3 (18.8) 27 (22.1) 81 (22.1)
Interstitial lung disease, n (%) 6 (7.5) 1 (7.7) 7 (53.8) 3 (18.8) 17 (13.9) 3 (0.8)
Treatment of RD, n (%)
Methotrexate 53 (66.3) 1 (7.7) 0 (0) 5 (31.3) 59 (48.4) N/A
Other DMARDs 57 (71.3) 6 (46.2) 2 (15.4) 6 (37.5) 71 (58.2) N/A
Corticosteroids 48 (60.0) 7 (58.3) 4 (30.8) 13 (81.3) 72 (59.0) N/A
TNF inhibitors 4 (5.0) 0 (0) 0 (0) 0 (0) 4 (3.3) N/A
Othersa 5 (6.3) 4 (30.8) 2 (15.4) 4 (25.0) 15(12.3) N/A
Data are expressed as the mean ± SD or as number (%)
Dx diagnosis, DMARD disease modifying antirheumatic drug, DM/PM dermatomyositis/polymyositis, N number, N/A not applicable, RA rheumatoid arthritis, RD
rheumatic disease, SLE systemic lupus erythematosus, SSc systemic sclerosis, TNF tumor necrosis factor, Yrs years
aOthers include tocilizumab, rituximab, abatacept, bucillamine, and cyclosporine
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for breast cancer (95 % CI, 4.24–20842.33) patients
when compared with matched controls without RD.
Strikingly, SSc was associated with decreased mortality
for lung cancer (HR 0.16; 95 % CI, 0.04–0.58).
Discussion
The present study shows that the mortality associated
with breast and lung cancer differs markedly depending
on the type of RD: patients with DM/PM with lung can-
cer had a much worse outcome than counterparts with-
out RD, whereas lung cancer patients with SSc had a
better outcome than those without RD.
Although all RDs arise due to defective immune re-
sponse with subsequent chronic inflammation, the dif-
ference in immune dysregulation with preferential
production of specific cytokines is associated with vary-
ing clinical manifestation [18]. Thus, RDs are classified
by the main site of involvement; RA and DM/PM in-
volve primarily joints and muscle, respectively, as the
main target organ. SSc is characterized by systemic fi-
brosis which is considered as an overshooting wound
healing [19, 20]. Inflammation of SLE is mediated by for-
mation and deposition of immune complexes in many
tissues, followed by subsequent complement activation
leading to organ damage [21]. Thus, the difference in
the immune dysregulation and the associated clinical
manifestations in individual RDs might influence their
cancer incidence and outcome [10].
Cancer survival depends mainly on cancer stage, co-
morbidities, and functional status at the time of cancer
diagnosis, all of which determine the treatment strategy
and outcome [17, 22]. Here, we found that the adjusted
Charlson comorbidity index (adjusted for the presence
of cancer and connective tissue disease) was worse only
for RD patients with colon and lung cancer when com-
pared with matched cancer patients without RD. The
ECOG performance status was similar between the RD
patients and matched cancer patients without RD
(Table 2). This finding suggests that underling RDs
might have little influence on performance status and
comorbidities in cancer patients.
Since RD patients are followed up more closely during
their longitudinal care, we expected that more cancers
would be detected at an early stage [7]. However, we
found that this was only the case for breast cancer. In
Korea, the National Cancer Screening Program (Korean
NCSP) recommends that women aged 40 years or over
undergo a screening mammogram once every 2 years.
The cumulative screening rate for breast cancer in eli-
gible women was reported as high as 77.9 % by 2012 in
Korea [23]. One might speculate that their underlying
chronic illness makes patients with RD more vigilant
about health issues; thus, they are more likely to follow
this recommendation, especially since they have better
access to health care services. Strikingly, there was no
difference in the stage of gastric cancer between RD and
non-RD groups. Chronic use of NSAIDs often leads to
Table 2 Baseline cancer-related characteristics of the 122 RD patients with cancer and the 366 age-, sex-, and cancer-matched controls
without RD



















≤1 28 (100.0) 81 (97.6) 1.000b 22 (95.7) 45 (65.2) 0.006b 34 (77.3) 119 (89.5) 0.041a 27 (100.0) 81 (100.0) 1.000b
≥2 0 (0) 2 (2.4) 1.000b 1 (4.3) 24 (34.8) 0.006b 10 (22.7) 14 (10.5) 0.041 a 0 (0) 0 (0) 1.000
Charlsond
0 16 (57.1) 54 (65.1) 0.501b 8 (34.8) 46 (66.7) 0.025b 22 (50.0) 90 (67.7) 0.047a 18 (66.7) 65 (80.2) 0.188b
1 5 (17.9) 17 (20.5) 1.000b 8 (34.8) 12 (17.4) 0.090b 12 (27.3) 22 (16.5) 0.127b 4 (14.8) 11 (13.6) 1.000b
≥2 7 (25.0) 12 (14.5) 0.246a 7 (30.4) 11 (15.9) 0.141b 11 (22.7) 21 (15.8) 0.180b 5 (18.5) 5 (6.2) 0.117b
Stage
I 13 (46.4) 41 (49.4) 0.830b 7 (30.4) 12 (17.4) 0.234b 14 (31.8) 27 (20.3) 0.149b 14 (51.9) 24 (29.6) 0.036a
II 6 (21.4) 15 (18.1) 0.781b 5 (21.7) 14 (20.3) 1.000b 5 (11.4) 77 (57.9) <0.001 b 10 (37.0) 44 (54.3) 0.120a
III 1 (3.6) 6 (7.2) 0.677b 4 (17.4) 23 (33.3) 0.190b 6 (13.6) 15 (11.3) 0.788 b 1 (3.7) 6 (7.4) 0.678b
IV 7 (25.0) 20 (24.1) 1.000b 7 (30.4) 18 (26.1) 0.788b 16 (36.4) 14 (10.5) <0.001 b 2 (7.4) 2 (2.5) 0.260b
NA 1 (3.6) 1 (1.2) 0.443b 0 (0) 2 (2.9) 1.000b 3 (6.8) 0 (0) 0.015 b 0 (0) 5 (6.2) 0.328b
Data are expressed as number (%)
F female, NA not applicable, RD rheumatic disease
aChi-square test, bFisher’s exact test
cEastern Cooperative Oncology Group (ECOG) performance status
dThe Charlson comorbidity index was adjusted for connective tissue disease and cancer
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Table 3 Cause of death of 45 patients with rheumatic disease and cancer
RD Cancer Cause of death Stage ECOGa Comorbidityb
1 DM/PM Breast Cancer progression 2 1 1
2 DM/PM Gastric Cancer progression 4 0 0
3 DM/PM Lung Cancer progression 1 0 0
4 DM/PM Lung Cancer progression 1 0 1
5 DM/PM Lung Cancer progression 2 2 1
6 DM/PM Lung Cancer progression 2 2 0
7 DM/PM Lung Cancer progression 3 2 0
8 DM/PM Lung Cancer progression NA 0 0
9 RA Breast Cancer progression 2 0 2
10 RA Breast Cancer progression 4 1 0
11 RA Breast Congestive Heart failure 1 0 1
12 RA Breast Old age 2 0 2
13 RA Colon Cancer progression 1 1 1
14 RA Colon Cancer progression 3 2 2
15 RA Colon Cancer progression 4 1 2
16 RA Lung Cancer progression 1 0 0
17 RA Lung Cancer progression 1 0 0
18 RA Lung Cancer progression 1 0 0
19 RA Lung Cancer progression 2 1 2
20 RA Lung Cancer progression 2 0 0
21 RA Lung Cancer progression 2 0 1
22 RA Lung Cancer progression 3 2 1
23 RA Lung Cancer progression 3 0 1
24 RA Lung Cancer progression 3 0 1
25 RA Lung Cancer progression 3 1 2
26 RA Lung Cancer progression 4 1 0
27 RA Lung Cancer progression 4 2 0
28 RA Lung Cancer progression 4 0 0
29 RA Lung Cancer progression 4 1 1
30 RA Lung Cancer progression 4 2 2
31 RA Lung Cancer progression 4 2 1
32 RA Lung Cancer progression 4 1 0
33 RA Lung Cancer progression 4 2 1
34 RA Lung Cancer progression 4 0 0
35 RA Lung Cancer progression 4 1 0
36 RA Lung Cancer progression 4 0 2
37 RA Lung Cancer progression NA 1 0
38 SLE Breast Cancer progression 4 1 0
39 SLE Colon Cancer progression 1 0 2
40 SSc Colon ILD aggrevation 3 1 2
41 SSc Lung Cancer progression 4 1 2
42 SSc Lung Cancer progression 4 2 1
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gastrointestinal discomfort; such patients are more likely
to undergo esophagogastroduodenoscopy (EGD), which
would detect “incidental” cancers at the early stage [24].
In Korea, the high prevalence of Helicobacter pylori and
associated gastritis and gastric cancer lower the thresh-
old for EGD, which is readily available at low cost. As
for breast cancer, the Korean NCSS offers gastric cancer
screening, which includes a double contrast barium
upper gastrointestinal series or EGD once every 2 years.
In 2012, the cumulative screening rate was reported to
be 77.9 % of the eligible people [23]. The lack of differ-
ence in gastric cancer staging between the RD-exposed
cohort and the non-RD-exposed cohort may be ex-
plained by the high screening rate for gastric cancer in
the general population in Korea [25]. Advanced lung
cancer was detected more often in patients with RD,
consistent with a prior report showing that up to 83 %
of lung cancers associated with connective tissue disease
Table 3 Cause of death of 45 patients with rheumatic disease and cancer (Continued)
43 SSc Lung Cancer progression 4 1 0
44 SSc Lung Cancer progression 4 0 0
45 SSc Lung Cancer progression NA 2 2
F female, NA not available, RD rheumatic disease, DM dermatomyositis, PM polymyositis, RA rheumatoid arthritis, SLE systemic lupus erythematosus, SSc systemic sclerosis
aAn Eastern Cooperative Oncology Group (ECOG) performance status
bThe Charlson comorbidity index was adjusted for connective tissue disease and cancer
Fig. 1 Kaplan-Meier survival curves for cancer patients with gastric cancer (a), colon cancer (b), lung cancer (c) and breast cancer (d) were
compared with those for matched cancer patients without rheumatic diseases. Tick marks indicate censoring events. The p value was calculated
using the log rank test. DM, dermatomyositis; ND, not determined; PM, polymyositis; RA, rheumatoid arthritis; RD, rheumatic disease; SLE, systemic
lupus erythematosus; SSc, systemic sclerosis.*p < 0.05, **p < 0.01 and ***p < 0.001 compared with the non-RD exposed cancer cohort
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were detected at stage IV [26]. As RD often affects the
lung in the form of ILD, the malignant mass might be
hidden by diffuse parenchymal changes until it manifests
clinically, leading to delayed cancer detection (Table 2)
[27]. Alternatively, the defective immune surveillance
associated with RD or immunosuppressive treatment fa-
cilitates rapid cancer progression. Of note, the Korean
NCSS does not recommend screening for lung cancer.
Overall, we found the similar (or at least no better) sta-
ging of cancer patients with RD and cancer-matched
controls without RD in the present study interesting,
and it raises questions as to whether patients with RD
might benefit from cancer screening guidelines tailored
to their underlying RD. Further studies are needed to
compare the cancer screening rates between patients
with RD and the general population.
The survival of lung cancer patients with RA or DM/
PM was worse than that for SSc patients and those with-
out RD (Fig. 1c). This is striking, since ILD, which was
present in 7 (53.8 %) SSc patients in the present study,
would negatively affect pulmonary function and, there-
fore, cancer outcome. As shown in Table 1, ILD de-
velops in a relatively low proportion of RA patients and
may be clinically asymptomatic [28]. ILD is rare as in
DM/PM patients with cancer, although it is present in
≥60 % DM/PM patients in general [29]. After adjusting
for cancer stage, comorbidities, performance status, age
at the time of cancer diagnosis, and ILD status, we
found that RA per se was associated with increased
mortality of lung cancer patients by 1.81-fold (95 CI,
1.03–3.18), whereas SSc was associated with decreased
mortality of lung cancer (HR, 0.16; 95 % CI, 0.04–0.58).
The results presented herein suggest that the additional
presence of ILD is not associated with a worse outcome
for lung cancer in patients with SSc. It is tempting to
speculate that the accumulation of autoimmune cells as-
sociated with ILD provides a harsh environment for can-
cer cells to grow [30, 31].
The overall mortality rate was high for breast cancer
patients with RA or DM/PM (Fig. 1d), when compared
with the cancer-matched controls without RD (Table 2,
bottom row), even though more breast cancers were
diagnosed at stage I. After adjusting for cancer stage, co-
morbidities, and performance status, DM/PM is associ-
ated with higher mortality of breast cancer, similar to a
prior report [32]. RA also tended to show a higher death
rate from breast cancer, suggesting that RA per se could
have a negative effect on cancer outcome (Fig. 2b). This
finding is consistent with those of prior studies showing
that patients with RA have a higher cancer-associated
mortality than the general population [33–35]. As both
RA and breast cancer are diseases that predominantly
affect women, changes in female hormone levels might
increase the aggressiveness of breast cancer in RA pa-
tients [36]. A common defect in the immune response
may lead to both autoimmunity and impaired cancer
surveillance. Ultimately, the mechanisms by which each
RD influences cancer physiology require further investi-
gation. As of now, given the worse prognosis for RD pa-
tients with particular cancers, more aggressive cancer
treatment tailored to the underlying RD should be the
subject of future studies.
The electronic medical records held at our institution
allow us to obtain reliable information regarding the
demographic and clinical characteristics of the both can-
cer and RD patients. In addition, the National Death
Register enables us to ascertain the survival status of all
enrolled patients. However, the study still has several
limitations. First, the relatively small cohort size results
in estimates with wide CI. Second, the current study de-
sign does not allow estimation of the effects of RD ther-
apy on cancer outcome of patients with corresponding
RD due to the tight collinearity between RD and RD
treatment. This is of particular interest, since the treat-
ment of RD focuses on the immune response, which ob-
viously plays a crucial in anti-tumor immunity. Third,
Fig. 2 Hazard ratios (HR) and 95 % confidence intervals for overall survival of patients with lung a or breast b cancer. HR was calculated by
adjusting for cancer stage, performance status, comorbidity index, and age at the time of cancer diagnosis. HR for lung cancer was adjusted also
for the presence of ILD. ND, not determined; DM, dermatomyositis; PM, polymyositis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus;
SSc, systemic sclerosis
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since cancer treatments vary, often at the discretion of
the treating physician, it was difficult to thoroughly
analyze the effects of cancer treatment on the survival
due to relatively small number of the patients. However,
we found that cancer patients with RD and those with-
out RD were treated with comparable aggressiveness ex-
cept for DM/PM patients with lung cancer; none (0 %)
of the 6 lung cancer patients with DM/PM underwent a
surgery as compared to the 58.6 % in the lung cancer pa-
tients without RD (Additional file 1: Table S2). These
limitations should be addressed in a larger prospective
study. Last but not the least, the survival analyses were
adjusted for Charles comorbidity index and ECOG,
although both index were not specifically designed to re-
flect the functional status of RDs. Retrospective nature
of this study did not allow us to collect RD-specific
functional status.
Conclusions
In conclusion, lung and breast cancer patients with RA
or DM/PM seemed to be associated with worse survival
than non-RD counterparts. Further studies will be
needed to address whether cancer treatments tailored to
specific RD can improve survival.
Additional file
Additional file 1: Supplementary material. Table S1. Interval
between rheumatic disease and cancer diagnosis in years. Table S2.
Cancer treatment according to rheumatic diseases. (DOCX 26 kb)
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